Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

18.8%

3 terminated/withdrawn out of 16 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

6%

1 trials in Phase 3/4

Results Transparency

300%

3 of 1 completed trials have results

Key Signals

4 recruiting3 with results

Enrollment Performance

Analytics

N/A
8(50.0%)
Phase 2
6(37.5%)
Early Phase 1
1(6.3%)
Phase 3
1(6.3%)
16Total
N/A(8)
Phase 2(6)
Early Phase 1(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials
NCT04984343Phase 2Terminated

Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer

Role: collaborator

NCT05108428Early Phase 1Active Not Recruiting

Adaptive Radiation for Locally Advanced Rectal Adenocarcinoma

Role: collaborator

NCT06077071Not ApplicableNot Yet Recruiting

MRIdian "RADAR" Trial

Role: collaborator

NCT04422132Phase 2Active Not Recruiting

Randomized Phase II Trial of Salvage Radiotherapy for Prostate Cancer In 4 Weeks v. 2 Weeks

Role: collaborator

NCT07223307Phase 2Recruiting

REGULUS: MRI-guided Adaptive SABR for Liver Cancers

Role: collaborator

NCT07276438Not ApplicableRecruiting

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

Role: collaborator

NCT07293585Phase 3Recruiting

Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment

Role: collaborator

NCT05301283Phase 2Recruiting

Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

Role: collaborator

NCT03541850Phase 2Active Not Recruiting

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

Role: collaborator

NCT04939246Not ApplicableCompleted

Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction

Role: collaborator

NCT04162665Phase 2Terminated

Pre-operative Adaptive Short Court Radiation Therapy in Gastric Cancer

Role: collaborator

NCT04376502Not ApplicableTerminated

Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.

Role: collaborator

NCT05585554Not ApplicableNot Yet Recruiting

Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy

Role: lead

NCT03621644Not ApplicableActive Not Recruiting

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

Role: lead

NCT05265663Not ApplicableUnknown

Stereotactic Radiotherapy vs Best Supportive Care in Unfit Pancreatic Cancer Patients

Role: collaborator

NCT04815694Not ApplicableUnknown

THeragnostic Utilities for Neoplastic DisEases of the Rectum by MRI Guided Radiotherapy

Role: collaborator

All 16 trials loaded